Turtle Creek Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Turtle Creek Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,189	Closed	-$237K	–	487
2025 Q4	$237K	Buy	+1,189	New	+$216K	0.02%	353
2024 Q1	–	Sell	-12	Closed	-$2.84K	–	329
2023 Q4	$2.84K	Buy	+12	New	+$2.36K	﹤0.01%	729

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Turtle Creek Wealth Advisors's CRL Position: Q1 2026 in Review

Turtle Creek Wealth Advisors sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 1,189 shares — an estimated $237K sold.

Turtle Creek Wealth Advisors first reported a position in CRL in Q4 2023 and held it in 2 quarters. The position peaked at $237K in Q4 2025. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Turtle Creek Wealth Advisors reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
Turtle Creek Wealth Advisors sold 1,189 Charles River Laboratories shares in Q1 2026, an estimated $237K.
Turtle Creek Wealth Advisors first reported a position in Charles River Laboratories in Q4 2023 and held it in 2 quarters.
Turtle Creek Wealth Advisors's Charles River Laboratories position peaked at $237K in Q4 2025.
558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Turtle Creek Wealth Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.